Vicente Valero Selected Research

Pathologic Complete Response

12/2022	Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
4/2022	A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
1/2022	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
1/2022	Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.
10/2021	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
1/2021	Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
1/2021	Update on systemic treatment for newly diagnosed inflammatory breast cancer.
1/2021	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
1/2021	Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
12/2020	Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vicente Valero Research Topics

Disease

189	Breast Neoplasms (Breast Cancer) 02/2022 - 01/2002
117	Neoplasms (Cancer) 01/2022 - 04/2002
41	Pathologic Complete Response 12/2022 - 06/2002
20	Triple Negative Breast Neoplasms 12/2022 - 09/2008
20	Inflammatory Breast Neoplasms 12/2021 - 08/2005
20	Neoplasm Metastasis (Metastasis) 11/2018 - 07/2002
10	Disease Progression 12/2018 - 04/2002
9	Residual Neoplasm 01/2022 - 01/2007
7	Cardiotoxicity 02/2022 - 11/2002
7	Fatigue 12/2021 - 02/2004
6	Carcinoma (Carcinomatosis) 10/2013 - 06/2005
5	Neutropenia 01/2021 - 02/2013
5	Circulating Neoplastic Cells 01/2020 - 07/2009
5	Fistula 01/2019 - 02/2016
4	Heart Failure 09/2019 - 11/2002
4	Pancreatic Fistula (Pancreatic Fistulas) 01/2019 - 02/2016
4	Lymphatic Metastasis 04/2016 - 03/2006
4	Lacrimal Apparatus Diseases (Epiphora) 06/2013 - 06/2002
4	Pathologic Constriction (Stenosis) 06/2013 - 06/2002
3	Noninfiltrating Intraductal Carcinoma (DCIS) 08/2019 - 11/2005
3	Febrile Neutropenia 01/2018 - 01/2011
3	Infections 02/2016 - 01/2006
3	Thrombocytopenia (Thrombopenia) 01/2011 - 07/2002
2	Left Ventricular Dysfunction 02/2022 - 11/2005
2	Brain Neoplasms (Brain Tumor) 03/2021 - 09/2006
2	Sepsis (Septicemia) 01/2021 - 04/2015
2	Fever (Fevers) 01/2021 - 07/2003
2	Necrosis 01/2021 - 01/2017
2	Frailty 03/2020 - 02/2015
2	Body Weight (Weight, Body) 03/2020 - 04/2007
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 02/2013
2	Margins of Excision 04/2018 - 02/2003
2	Stroke (Strokes) 01/2018 - 06/2015
2	Adenocarcinoma 12/2016 - 09/2014
2	Renal Insufficiency (Renal Failure) 06/2015 - 01/2015

Drug/Important Bio-Agent (IBA)

31	Trastuzumab (Herceptin)FDA Link 02/2022 - 04/2002
30	Estrogen ReceptorsIBA 10/2021 - 05/2002
29	AnthracyclinesIBA 01/2022 - 04/2002
27	Hormones (Hormone)IBA 01/2022 - 09/2004
24	Docetaxel (Taxotere)FDA Link 01/2019 - 01/2002
22	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 06/2002
21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 06/2002
18	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 05/2002
18	taxaneIBA 01/2021 - 03/2003
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2005
15	human ERBB2 proteinIBA 12/2021 - 12/2009
14	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 05/2002
12	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2007
12	Progesterone Receptors (Progesterone Receptor)IBA 10/2020 - 02/2003
10	Capecitabine (Xeloda)FDA Link 07/2019 - 08/2003
10	Tamoxifen FDA LinkGeneric 01/2016 - 05/2002
9	Estrogens (Estrogen)FDA Link 01/2019 - 02/2003
8	Taxoids (Taxanes)IBA 01/2020 - 05/2002
8	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 01/2011
8	Biological ProductsIBA 06/2017 - 06/2005
7	Ado-Trastuzumab EmtansineIBA 02/2022 - 10/2016
7	pertuzumabIBA 10/2021 - 10/2016
6	Epidermal Growth Factor (EGF)IBA 10/2020 - 06/2011
6	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2004
6	Bevacizumab (Avastin)FDA Link 04/2017 - 07/2010
6	Pharmaceutical PreparationsIBA 01/2017 - 09/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2008
5	ixabepilone (BMS 247550)FDA Link 10/2015 - 01/2011
5	Messenger RNA (mRNA)IBA 01/2013 - 01/2007
4	Epirubicin (Ellence)FDA LinkGeneric 01/2021 - 01/2007
4	Lapatinib (GW572016)FDA Link 07/2019 - 07/2010
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 01/2008
4	Gemcitabine FDA Link 01/2018 - 09/2003
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2017 - 01/2002
4	Phenobarbital (Luminal)FDA Link 03/2017 - 05/2009
4	Anastrozole (Arimidex)FDA LinkGeneric 02/2012 - 06/2002
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2015
3	liposomal doxorubicin (Doxil)FDA Link 04/2017 - 04/2002
3	Selective Estrogen Receptor Modulators (SERM)IBA 01/2016 - 03/2004
3	Aromatase InhibitorsIBA 02/2012 - 03/2004
2	Dexamethasone (Maxidex)FDA LinkGeneric 12/2021 - 08/2006
2	CytokinesIBA 08/2019 - 02/2004
2	Letrozole (Femara)FDA LinkGeneric 07/2019 - 12/2018
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019 - 07/2009
2	exemestane (Aromasin)FDA Link 01/2019 - 03/2004
2	N-acetyltalosaminuronic acid (NAT)IBA 11/2018 - 09/2015
2	tipifarnib (R115777)IBA 01/2018 - 10/2013
2	Keratins (Keratin)IBA 12/2016 - 11/2005
2	Indicators and Reagents (Reagents)IBA 08/2016 - 01/2016
2	Methotrexate (Mexate)FDA LinkGeneric 12/2015 - 03/2010

Therapy/Procedure

75	Therapeutics 01/2022 - 04/2002
67	Drug Therapy (Chemotherapy) 01/2022 - 04/2002
58	Neoadjuvant Therapy 12/2022 - 07/2002
20	Radiotherapy 04/2018 - 07/2002
12	Mastectomy (Mammectomy) 08/2021 - 07/2002
8	Adjuvant Chemotherapy 01/2019 - 05/2002
7	Segmental Mastectomy (Lumpectomy) 04/2018 - 10/2002
5	Aftercare (After-Treatment) 01/2018 - 07/2002
5	Mammaplasty (Breast Reconstruction) 03/2017 - 12/2008
4	Combination Drug Therapy (Combination Chemotherapy) 12/2014 - 04/2010
3	Pancreatectomy 01/2019 - 02/2015
3	Pancreaticoduodenectomy 01/2018 - 02/2016
3	Transplantation 06/2015 - 01/2015
2	Lymph Node Excision (Lymph Node Dissection) 09/2020 - 07/2008
2	Simple Mastectomy 02/2016 - 12/2008